Sep, 24 2019 10:01 JST

Source: Eisai

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress


TOKYO, Sep, 24 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019. The abstracts highlight updates regarding Eisai's in-house discovered LENVIMA (lenvatinib mesylate, the orally available kinase inhibitor, "lenvatinib"), and Halaven (eribulin mesylate, "eribulin", halichondrin class microtubule dynamics inhibitor).

At the ESMO 2019 Congress, there will be an oral presentation of results from the final analysis of the endometrial carcinoma cohort of Study 111/KEYNOTE-146, a Phase Ib/II study evaluating the combination treatment of lenvatinib and Merck & Co., Inc., Kenilworth, NJ., U.S.A.'s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in select solid tumors (Abstract No.: 994O). The combination treatment was the first to be approved in the United States, Australia and Canada under the U.S. Food and Drug Administration's Project Orbis in Sept 2019

A total of 11 poster presentations are scheduled, including one on the updated results of the lenvatinib plus pembrolizumab combination treatment in unresectable hepatocellular carcinoma in study 116/KEYNOTE- 524, a Phase 1b study (Abstract No.: 747P), and the interim analysis evaluating the combination after disease progression after PD-1/PD-L1 immune checkpoint blockade in renal cell carcinoma (RCC) from 111/KEYNOTE-146 RCC cohort (Abstract No.: 1187PD). In addition, the latest data from a Phase I study for an eribulin liposomal formulation in solid tumors (Abstract No.: 348P) will be presented.

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.


Contact:
Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
November 05 2019 09:02 JST
 
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
October 23 2019 10:13 JST
 
Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
October 15 2019 20:24 JST
 
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
October 01 2019 10:46 JST
 
Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China
September 30 2019 11:06 JST
 
Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia
September 26 2019 13:21 JST
 
Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients
September 26 2019 13:08 JST
 
Eisai and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safinamide Mesilate) Approved In Japan
September 20 2019 15:13 JST
 
Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India
September 20 2019 08:40 JST
 
Eisai to Present Latest Data on Lemborexant at World Sleep Congress
September 19 2019 19:06 JST
 
More Press release >>

Latest Press Release


More Latest Release >>